Tekla Life Sciences Investors
Tekla Life Sciences Investors (HQL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hql · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Tekla Life Sciences Investors (HQL) measures how much investors pay for each dollar of the company's trailing earnings. HQL's current PE ratio of 5.65x is calculated by dividing its stock price of $16.73 by its TTM earnings per share of $2.96. −24.0% discount vs 5Y avg 7.4x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 15 fiscal years · Front-end computedMinQ1 · 25%0.0x
MedianQ3 · 75%15.9x
Max
At 5.65x, HQL's current P/E is within its average historical range over the past 15 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Asset Management · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Tekla Life Sciences InvestorsYou HQL | $509M | 5.65x | -97.8% | $2.96 |
 Crescent Capital BDC, Inc. CCAP | $408M | 15.08x | -94.1% | $0.93 |
 CION Investment Corporation CION | $344M | N/A | — | -$0.39 |
 Eagle Point Credit Company Inc. ECC | $532M | N/A | — | -$1.05 |
 Gladstone Investment Corporation GAIN | $606M | 2.98x | -98.8% | $4.77 |
 GigCapital7 Corp. GIG | $172M | 988.58x | +289.6% | $0.01 |
 Gladstone Capital Corporation GLAD | $428M | 8.41x | -96.7% | $2.60 |
Industry Average 4 peers with valid PE | — | 253.76x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | 5.23x | $2.96 | +5.5% | |
2024-09-30 FY2024 | 4.96x | $3.04 | -68.6% | |
2023-09-30 FY2023 | 15.78x | $0.79 | — | |
2022-09-30 FY2022 | — | $-4.07 | — | |
2021-09-30 FY2021 | 7.82x | $2.66 | +129.5% | |
2020-09-30 FY2020 | 3.41x | $5.16 | — | |
2019-09-30 FY2019 | — | $-3.04 | — | |
2018-09-30 FY2018 | 15.91x | $1.28 | +137.7% | |
2017-09-30 FY2017 | 6.69x | $3.21 | — | |
2016-09-30 FY2016 | — | $-1.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Tekla Life Sciences Investors (HQL) measures how much investors pay for each dollar of the company's trailing earnings. HQL's current PE ratio of 5.65x is calculated by dividing its stock price of $16.73 by its TTM earnings per share of $2.96.
Frequently asked questions
HQL pe ratio · 6 questionsHQL's current PE ratio is 5.65x as of 2026-06-08, based on a stock price of $16.73 and TTM EPS of $2.96. Data sourced from Financial Modeling Prep via HQL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Tekla Life Sciences Investors SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08